While both are cell-based modalities, TCR-T identity assays must confirm the precise expression of both the alpha and beta chains of the engineered T-cell receptor. This is a more complex validation target than the single-chain variable fragment (scFv) typical of a CAR construct. Assays must be designed to specifically detect the engineered receptor without cross-reacting with endogenous TCRs.

For an IMPD or other multi-jurisdictional submissions, purity assays must adhere to harmonized ICH guidelines. Key considerations include quantifying the percentage of viable, correctly transduced T-cells, measuring residual components from the manufacturing process (e.g., viral vectors, cytokines), and assessing the presence of non-transduced or improperly activated T-cell populations. All methods must be qualified or validated in a phase-appropriate manner.

Yes. A well-defined potency assay is a regulatory expectation. We develop custom, cell-based assays that measure the functional response of the TCR-T product upon engagement with its specific peptide-MHC target. This provides a quantitative measure of biological activity, which is a core component of the overall CMC data package.

The analytical strategy for TCR-T engineered therapies is foundational to minimizing clinical risk and achieving regulatory milestones. The therapeutic hypothesis of a TCR-T product rests on the high-fidelity expression of a specific alpha-beta chain pairing designed to recognize a distinct peptide-MHC complex.

Defining product identity requires a multi-faceted approach. It is insufficient to simply confirm T-cell lineage. The analytical methods must definitively verify the presence and expression of the intended transgenic TCR. This is typically accomplished through a combination of techniques:

* **Flow Cytometry:** Utilizes specific antibodies or tetramers to identify the surface expression of the engineered TCR.

* **Quantitative PCR (qPCR/ddPCR):** Measures the transcript levels of the introduced alpha and beta chains, providing data on vector copy number and transgene expression.

* **Next-Generation Sequencing (NGS):** Offers high-resolution confirmation of the integrated TCR sequence and can identify potential integration site anomalies.

Purity assessments are equally important for de-risking the therapeutic program. These assays quantify the proportion of the desired TCR-T cell population relative to other cells in the final product. This includes non-transduced T-cells, cells transduced with a non-functional vector, or other contaminating cell types. A clear understanding of product purity is a regulatory expectation and informs dose calculations.

The development of such precise analytical tools is a core competency at Franklin Biolabs, supported by our work with partners like our partners and our extensive experience across next-generation therapies. The strategic need for developing robust, high-sensitivity assays for regulatory submissions is a well-understood principle (PMID: 39282076). Confirming a potent and specific T-cell response is the central mechanism of action for these products, a concept validated in adjacent fields of immunology (PMID: 18788905).

Our teams operate within a >100,000 sq ft facility designed for these complex analytical and preclinical programs `

`. This infrastructure allows us to integrate CMC analytics directly with IND-enabling toxicology studies, aligning the entire program toward an 18-24 month timeline to IND. This integrated approach builds a comprehensive analytical data package that supports the product’s quality, function, and safety profile for global regulatory bodies.

For more information on our comprehensive analytical capabilities, please see our main services page: [Vector | CMC | Analytics Services](/vector-cmc-analytics-services_7.md).

—

***